Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK Biologicals' influenza vaccine GSK2186877A · 1 trial · 1 indication
The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)
| Arm | Type | Description |
|---|---|---|
| New generation influenza vaccine GSK2186877A Group | EXPERIMENTAL | Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0 |
| Fluarix elderly Group | ACTIVE_COMPARATOR | Subjects aged \>= 65 years receiving 1 dose of Fluarix vaccine at Day 0 |
| Fluarix young Group | ACTIVE_COMPARATOR | Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0 |
| Name | Type | Description |
|---|---|---|
| GSK Biologicals' influenza vaccine GSK2186877A | BIOLOGICAL | One intramuscular injection at Day 0 |
| GSK Biologicals' Fluarix | BIOLOGICAL | One intramuscular injection at Day 0 |
Inclusion Criteria: All subjects must satisfy the following criteria at study entry: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of subje...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
GSK Biologicals' influenza vaccine GSK2186877A is an investigational vaccine developed by GSK plc for the prevention of influenza. It is a Phase 3 candidate in the infectious disease therapeutic area. The vaccine has been studied in a completed Phase 3 trial in adults aged 65 years or older.
GSK2186877A is being developed for the prevention of influenza. It is intended to protect against influenza infection, with clinical evaluation focused on people aged 65 years or older. The vaccine remains investigational and has not been approved for use.
GSK2186877A is made by GSK plc, which trades under the ticker GSK. The vaccine is developed by GSK Biologicals, the company's vaccines division. GSK plc is the sponsor responsible for the clinical development of this influenza vaccine candidate.
GSK2186877A is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The vaccine is investigational and has not been approved by the FDA or any regulatory authority for the prevention of influenza.
GSK2186877A has been evaluated in one completed Phase 3 trial, NCT00765076, titled a clinical study of the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older. The trial enrolled 192 participants across the United States and Spain.
The Phase 3 trial NCT00765076 was a randomized, double-blind, active-controlled study of GSK2186877A in people aged 65 years or older. It enrolled 192 participants in the United States and Spain and has been completed. The study assessed immunogenicity in healthy volunteers.